Skip to main content Skip to main navigation menu Skip to site footer
International Journal of Nutrology
Articles
DOI: 10.1055/s-0040-1705631
Submitted: 02-07-2022
Published: 02-07-2022

A importância da idade na síndrome metabólica em pacientes portadoras de ovários policísticos

Médico do Programa Saúde da Família – Aracaju (SE), Brasil
Médica Pediatra – Aracaju (SE), Brasil
Acadêmico do Curso de Medicina da Universidade Federal de Sergipe (UFS) – Aracaju (SE), Brasil
Acadêmico do Curso de Medicina da Universidade Federal de Sergipe (UFS) – Aracaju (SE), Brasil
Professora PhD de Ginecologia e Obstetrícia do Departamento de Medicina da Universidade Federal de Sergipe (UFS) – Aracaju (SE), Brasil
Polycystic ovary syndrome Metabolic syndrome Cardiovascular diseases

Abstract

This study aims to evaluate the prevalence and individual characteristics of the metabolic syndrome (MBS) in sergipanas women with polycystic ovary syndrome (PCOS) using age as an association variable. It is a cross-sectional study involving 50 women aged 25-50 years old with PCOS in accord with Rotterdam criteria (2003). For the diagnosis of metabolic syndrome, the National Cholesterol Education Program's Adult Treatment Panel III (NCEP-ATP III) was considered. The prevalence of the MBS was 56%. As for the individual components of MS, was evident: abdominal circumference > 88 cm in 72%, triglycerides ≥ 150 mg/dL in 32%, HDL-cholesterol <50 mg/dl in 54%, fasting glucose ≥ 110 mg/dl in 26%, systolic blood pressure ≥ 130 mmHg in 52% and diastolic blood pressure ≥ 85 mmHg in 40%. Patients aged equal or over 35 years had a higher percentage of Abdominal Circumference (AC) > 88 cm (40%), modified triglyceride levels (20%), HDL-cholesterol to levels below 50 mg/dl (34%), altered levels of fasting glucose (22%), systolic blood pressure (SBP) equal to or above 130 mmHg (36%) and diastolic blood pressure (DBP) equal to or above 85 mmHg (26%). There was a statistically significant association (p <0.05) between age and the following variables: AC, triglycerides, fasting glucose and DBP. There was a significant prevalence of MS in more than half the women studied, indicating increased chances for developing cardiovascular disease (CVD) and pointing out the need for tracking cardiovascular risk among women with clinical manifestations of PCOS.

Metrics

Metrics Loading ...

References

  1. Gadelha RGN, Soares EMM, Silva TMA, Maranhão TMO, Azevedo GD. Síndrome dos ovários policísticos e síndrome: uma associação significativa com implicações clínicas. PublICa. 2005;1(2):68-77.
  2. Fernandes LG. Síndrome dos ovários policísticos: uma abordagem epidemiológica [tese]. Salvador (BA): Universidade Federal da Bahia, Instituto de Saúde Coletiva, Programa de Pós-Graduação em Saúde Coletiva; 2013.
  3. Legro RS. Diagnostic criteria in polycystic ovary syndrome. Seminars in reproductive medicine. 2003;21(3):267-75.
  4. Speroff LGR, Kase NG. Anovulation and the Polycystic Ovary. In: Weinberg R, editor. Clinical Gynecologic Endocrinology and Infertility. Philadelphia: Lippincott Williams and Wilkins; 2005. p.465-98.
  5. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005;352(12):1223-36.
  6. Cussons AJ, Stuckey BG, Watts GF. Cardiovascular disease in the polycystic ovary syndrome: new insights and perspectives. Atherosclerosis. 2006;185(2):227-39.
  7. Fernández-Morales D. Manifestaciones clínicas del síndrome del ovario poliquístico. Acta Médica Costarricense. 2005;47(4):180-5.
  8. Bhatia V. Insulin resistance in polycystic ovary disease. South Med J. 2005;98(9):903-10.
  9. Vrbikova J, Cibula D, Dvorakova K, Stanicka S, Sindelka G, Hill M, et al. Insulin Sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2004;89(6):2942-5.
  10. Trolle B, Lauszus FF. Risk factors for glucose intolerance in Danish women with polycystic ovary syndrome. Acta Obstet Gynecol Scand. 2005;84(12):1192-6.
  11. Wild S, Pierpoint T, McKeighe P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxf). 2000;52(5):595-600.
  12. Legro RS. Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocr Rev. 2003;24(3):302-12.
  13. Meyer C, McGrath BP, Teede HJ. Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease. J Clin Endocrinol Metab. 2005;90(10): 5711-6.
  14. Soares EM, Azevedo GD, Gadelha RG, Lemos TM, Maranhão TM. Prevalence of the metabolic syndrome and its components in Brazilian women with polycystic ovary syndrome. Fertil Steril. 2008;89(3):649-55.
  15. Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN, et al. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91(1):48-53.
  16. Meirelles RMR. Menopausa e síndrome metabólica. Arq Bras Endocrinol Metab. 2014;58(2):91-6.
  17. Hildrum B, Mykletun A, Hole T, Midthjell K, Dahl AA. Age-specific prevalence of the metabolic syndrome defined by the International Diabetes Federation and the National Cholesterol Education Program: the Norwegian HUNT 2 study. BMC Pub. Health. 2007;7(220):1-9.
  18. Szostak-Wegierek D, Waskiewicz A. Metabolic disorders in women at procreative age living in Warsaw. Rocz Panstw Zakl Hig. 2015;66(3):245-251.
  19. Soares EMM, Azevedo GD, Maranhão TMO. Síndrome Metabólica em Mulheres Com Síndrome dos Ovários Policísticos: Prevalência em Cidade da Região Nordeste do Brasil. Arq Bras Endocrinol Metab. 2007;51(6):1027:1028.
  20. Gogia A, Agarwal PK. Metabolic syndrome. Indian J Med Sci. 2006;60(2):72-81.
  21. Vural B, Caliskan E, Turkoz E, Kilic T, Demirci A. Evaluation of metabolic syndrome frequency and premature carotid atherosclerosis in young women with polycystic ovary syndrome. Hum Reprod. 2005;20(9):2409-13.
  22. Tehrani FR, Montazeri1 SA, Hosseinpanah F, Cheraghi L, Erfani1 H, Tohidi M, et al. Trend of Cardio-Metabolic Risk Factors in Polycystic Ovary Syndrome: A Population-Based Prospective Cohort Study. PLoS ONE. 2015;10(9):1-16.
  23. Costa LOBF, Viana AOR, Oliveira M. Prevalência da síndrome metabólica em portadoras da síndrome dos ovários policísticos. Rev Bras Ginecol Obstet. 2007;29(1):10–17.
  24. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19-25.
  25. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-421.
  26. Puder JJ, Varga S, Kraenzlin M, de Geyter C, Keller U, Müller B. Central fat excess in polycystic ovary syndrome: relation to low-grade inflammation and insulin resistance. J Clin Endocrinol Metab. 2005;90(4):6014-21.
  27. Centers for Disease Control and Prevention. The Third National Health and Nutrition Examination Survey (NHANES III 1988-94) Reference Manuals and Reports. Bethesda, Md: National Center for Health Statistics; 1996.
  28. Ilanne-Parrika P, Eriksson JG, Lindstrom J, Hamalainen H, Keinanen-Kiukaanniemi S, Laakso M, et al. Prevalence of the Metabolic Syndrome and its Components. Diabetes Care. 2004;27(9):2135-40.
  29. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA. 2002;287(3):356-9.
  30. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the Metabolic Syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90(4):1929-35.
  31. Ávila MAP, Bruno RV, Barbosa FC, Andrade FC, Silva ACO, Nardi AE. Síndrome dos ovários policísticos: implicações da disfunção metabólica. Rev Col Bras Cir. 2014;41(2):106-11.
  32. Premoli ACG, Moura MD, Ferriani RA, Sá MFS, Reis RM. Perfil lipídico em pacientes portadoras da síndrome dos ovários policísticos. Rev Bras Ginecol Obstetr. 2000;22(2):89-94.
  33. Sathyapalan T, Atkin SL. Mediators of inflammation in polycystic ovary syndrome in relation to adiposity. Mediators inflammation. 2010;2010:1-5.
  34. Costa EC, Soares EMM, Lemos TMAM, Maranhão TMO, Azevedo GD. Índices de obesidad central y factores de riesgo cardiovascular em el síndrome de ovarios poliquísticos. Arq Bras Cardiol. 2010;94(5):615–20.
  35. Kandaraki E, Christakou C, Diamanti-Kandarakis E. Metabolic syndrome and polycystic ovary syndrome… and vice versa. Arq Bras Endocrinol Metab. 2009;53(2):227-37.
  36. Kuba VM, Cavaliere PM, Christóforo AC, Faria Júnior R, Caetano R, Coeli CM, et al. Resistência insulínica e perfil metabólico em pacientes com síndrome dos ovários policísticos de peso normal e sobrepeso/obesidade. Arq Bras Endocrinol Metab. 2006;50(6):1026–33.
  37. Baldani DP, Skrgatic L, Ougouag Roya. Polycystic ovary syndrome: important underrecognised cardiometabolic risk factor in reproductive-age women. Inter J Endocrinol. 2015;2015:1-17.
  38. Martins WP, Soares GM, Vieira CS, Reis RM, Sá MFS, Ferriani RA. Resistência à insulina em mulheres com síndrome dos ovários policísticos modifica fatores de risco cardiovascular. Rev Bras Ginecol Obstet. 2009;31(3):111–6.
  39. Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med. 2001;111(8):607-13.
  40. Hudecova M, Holte J, Olovsson M, Larsson A, Berne C, Sundstrom-Paromaa I. Prevalence of the metabolic syndrome in women with a previous diagnosis of polycystic ovary syndrome: long-term follow-up. Fertility and Sterility. 2011;96(5):1271-4.
  41. Gobato AO, Vasques ACJ, Zambon MP, Barros Filho AA, Hessel G. Síndrome metabólica e resistência à insulina em adolescentes obesos. Rev Paul Pediatr. 2014;32(1):55-62.
  42. Passos VMA, Assis TD, Barreto SM. Hipertensão arterial no Brasil: estimativa de prevalência a partir de estudos de base populacional. Epidemiol Serv Saúde. 2006;15(1):35-45.
  43. Dias-da-Costa JS, Olinto MTA, Patrussi AT. Prevalência de hipertensão arterial sistêmica e fatores associados: um estudo de base populacional em mulheres no Sul do Brasil. Cad Saúde Púb. 2007;23(8):1857-66.
  44. Faramawi MF, Delongchamp R, Said Q, Jadhav S, Abouelenien S. Metabolic syndrome is associated with visit-to-visit systolic blood pressure variability in the US adults. Hypertens Res. 2014;37(9):875-9.

How to Cite

Cavalcante, B. G. C. de H., Gois, L. H. M., Santos, J. G. C., Silva, R. A. da, & Dias, J. M. G. (2022). A importância da idade na síndrome metabólica em pacientes portadoras de ovários policísticos. International Journal of Nutrology, 9(2), 199–208. https://doi.org/10.1055/s-0040-1705631